eFFECTOR Therapeutics Management

Management criteria checks 2/4

eFFECTOR Therapeutics' El consejero delegado es Steve Worland , nombrado en May 2012, tiene un mandato de 11.58 años. la remuneración anual total es $3.84M , compuesta por 14.7% salario y 85.3% primas, incluidas acciones y opciones de la empresa. posee directamente 1.28% de las acciones de la empresa, por valor de $323.94K . La antigüedad media del equipo directivo y del consejo de administración es de 2.2 años y 2.3 años respectivamente.

Key information

Steve Worland

Chief executive officer

US$1.2m

Total compensation

CEO salary percentage	48.8%
CEO tenure	11.9yrs
CEO ownership	0.9%
Management average tenure	3.3yrs
Board average tenure	2.7yrs

Recent management updates

Recent updates

eFFECTOR doses first patient in second cohort of phase 1b trial of potential COVID drug

Sep 14

eFFECTOR Therapeutics GAAP EPS of -$0.17

Aug 09

eFFECTOR: Developing New Class Of Cancer Therapies

Sep 12

CEO Compensation Analysis

How has Steve Worland's remuneration changed compared to eFFECTOR Therapeutics's earnings?
Date	Total Compensation	Salary	Company Earnings
Dec 31 2023	US$1m	US$595k	-US$36m
Sep 30 2023	n/a	n/a	-US$36m
Jun 30 2023	n/a	n/a	-US$37m
Mar 31 2023	n/a	n/a	-US$36m
Dec 31 2022	US$4m	US$567k	-US$23m
Sep 30 2022	n/a	n/a	US$6m
Jun 30 2022	n/a	n/a	US$24m
Mar 31 2022	n/a	n/a	US$25m
Dec 31 2021	US$3m	US$501k	US$16m
Sep 30 2021	n/a	n/a	-US$4m
Jun 30 2021	n/a	n/a	-US$20m
Mar 31 2021	n/a	n/a	-US$7m
Dec 31 2020	US$645k	US$452k	US$166k

Compensación vs. Mercado: Steve($USD3.84M) está por encima de la media de empresas de tamaño similar en el mercado US ($USD738.70K).

Compensación vs. Ingresos: La compensación de Steve ha sido consistente con los resultados de la empresa en el último año.

CEO

Steve Worland (65 yo)

11.9yrs

Tenure

US$1,217,505

Compensation

Dr. Stephen T. Worland, also known as Steve, Ph.D. serves as Director at Blacksmith Medicines, Inc. He has been President and Chief Executive Officer of eFFECTOR Therapeutics, Inc. since May 2012 and has b...

Leadership Team

Name	Position	Tenure	Compensation	Ownership
Stephen Worland	CEO, President & Director	11.9yrs	US$1.22m	0.90% $ 98.2k
Michael Byrnes	Chief Financial Officer	3.3yrs	US$826.59k	0.047% $ 5.1k
Douglas Warner	Chief Medical Officer	1.7yrs	US$746.04k	0% $ 0
Davide Ruggero	Co-Founder and Member of Clinical & Scientific Advisory Board	no data	no data	no data
Kevan Shokat	Co-Founder and Member of Clinical & Scientific Advisory Board	no data	no data	no data

3.3yrs

Average Tenure

51yo

Average Age

Equipo directivo experimentado: EFTREl equipo directivo de la empresa se considera experimentado (2.2 años de antigüedad media).

Board Members

Name	Position	Tenure	Compensation	Ownership
Stephen Worland	CEO, President & Director	2.7yrs	US$1.22m	0.90% $ 98.2k
Davide Ruggero	Co-Founder and Member of Clinical & Scientific Advisory Board	no data	no data	no data
Kevan Shokat	Co-Founder and Member of Clinical & Scientific Advisory Board	no data	no data	no data
Christopher Ehrlich	Independent Director	2.7yrs	US$80.86k	0.19% $ 21.1k
Neal Rosen	Member of Clinical & Scientific Advisory Board	no data	no data	no data
Caroline Loewy	Independent Director	less than a year	US$35.70k	0.0098% $ 1.1k
Joan Brugge	Member of Clinical & Scientific Advisory Board	no data	no data	no data
Jennifer Doudna	Member of Clinical & Scientific Advisory Board	no data	no data	no data
Kapil Dhingra	Member of Clinical & Scientific Advisory Board	no data	no data	no data
Brian Gallagher	Independent Chairman	4.3yrs	US$109.82k	0.033% $ 3.6k
Elizabeth Bhatt	Independent Director	3.3yrs	US$74.58k	0.0098% $ 1.1k
Funda Meric-Bernstam	Member of Clinical & Scientific Advisory Board	no data	no data	no data

2.7yrs

Average Tenure

57.5yo

Average Age

Junta con experiencia: EFTRno se consideran experimentados ( 2.3 años de permanencia media), lo que sugiere un nuevo consejo.

eFFECTOR Therapeutics Management

Management criteria checks 2/4

Key information

Recent management updates

eFFECTOR Therapeutics, Inc. Appoints Caroline Loewy to its Board of Directors

eFFECTOR Therapeutics, Inc., Annual General Meeting, Jun 22, 2023

High number of new directors

Effector Therapeutics Appoints Mayank Gandhi, M.D., as Chief Business Officer

eFFECTOR Therapeutics Appoints Douglas Warner as Chief Medical Officer

eFFECTOR Therapeutics, Inc. Announces Executive Changes

Recent updates

New major risk - Share price stability

eFFECTOR Therapeutics, Inc. Announces Topline Results of Phase 2 KICKSTART Trial of Tomivosertib Combined with Pembrolizumab in Non-Small Cell Lung Cancer

Price target decreased by 92% to US$22.50

New major risk - Share price stability

eFFECTOR Therapeutics, Inc. has completed a Follow-on Equity Offering in the amount of $15.000003 million.

Price target increased by 90% to US$275

eFFECTOR Therapeutics, Inc. has filed a Follow-on Equity Offering in the amount of $15.000003 million.

eFFECTOR Therapeutics, Inc. Announces New Positive Interim Data from Dose Escalation and Phase 2 Expansion Cohorts of Zotatifin in Er+ Metastatic Breast Cancer Patients

eFFECTOR Therapeutics, Inc. Receives U.S. FDA Fast Track Designation for Zotatifin in Combination with Fulvestrant and Abemaciclib for Treatment of Er+/Her2- Advanced Metastatic Breast Cancer

New major risk - Shareholder dilution

Third quarter 2023 earnings released: US$0.13 loss per share (vs US$0.23 loss in 3Q 2022)

Effector Therapeutics, Inc. Announces Initiation of Dosing in an Investigator-Initiated Phase 1 Dose Escalation Trial Evaluating Tomivosertib in Patients with Relapsed/Refractory Acute Myeloid Leukemia (Aml)

eFFECTOR Therapeutics, Inc. Appoints Caroline Loewy to its Board of Directors

Price target decreased by 11% to US$6.58

eFFECTOR Therapeutics Receives Non-Compliance Notice from Nasdaq Stock Market Regarding Non-Compliance with Nasdaq's Minimum Bid Price Requirement

eFFECTOR Therapeutics, Inc. has completed a Follow-on Equity Offering in the amount of $8.733186 million.

eFFECTOR Therapeutics, Inc. has completed a Follow-on Equity Offering in the amount of $7.49325 million.

eFFECTOR Therapeutics, Inc. has completed a Follow-on Equity Offering in the amount of $7.49325 million.

Price target increased by 17% to US$7.38

eFFECTOR Therapeutics Receives Non-Compliance Notice from Nasdaq

eFFECTOR Therapeutics, Inc., Annual General Meeting, Jun 22, 2023

Price target increased by 16% to US$6.33

eFFECTOR Therapeutics, Inc. Provides Positive Clinical Data Update for Zotatifin and General Corporate Update

Price target decreased to US$8.60

Price target increased to US$10.75

High number of new directors

Effector Therapeutics Completes Enrollment in Second of Three Cohorts of Phase 1B Clinical Trial of Zotatifin for the Treatment of Covid-19

Effector Therapeutics Appoints Mayank Gandhi, M.D., as Chief Business Officer

eFFECTOR Therapeutics, Inc. Doses First Patient in Second Cohort of Phase 1B Clinical Trial of Zotatifin for the Treatment of Covid-19

eFFECTOR doses first patient in second cohort of phase 1b trial of potential COVID drug

eFFECTOR Therapeutics Receives A Letter from the Nasdaq Stock Market Staff

Consensus forecasts updated

Price target decreased to US$10.68

eFFECTOR Therapeutics GAAP EPS of -$0.17

eFFECTOR Therapeutics Appoints Douglas Warner as Chief Medical Officer

eFFECTOR Therapeutics, Inc. Announces Executive Changes

Investor sentiment deteriorated over the past week

eFFECTOR Therapeutics, Inc. Reports Positive Interim Results in Zotatifin (eFT226) Phase 1/2 Clinical Trial at ASCO 2022 Showing Safety and Tolerability, and Initial Signals of Clinical Activity

Investor sentiment improved over the past week

eFFECTOR Therapeutics, Inc. Announces Interim Data from Its Ongoing Phase 1/2 Clinical Trial of Zotatifin in Solid Tumors

Consensus forecasts updated

Investor sentiment deteriorated over the past week

High number of new directors

eFFECTOR Therapeutics, Inc., Annual General Meeting, Jun 09, 2022

eFFECTOR Therapeutics, Inc. Announces Transition in Clinical Leadership

Consensus forecasts updated

Investor sentiment improved over the past week

Full year 2021 earnings: Revenues exceed analysts expectations while EPS lags behind

eFFECTOR Therapeutics, Inc. Announces Directorate Changes

eFFECTOR Therapeutics, Inc. Provides Pipeline and Business Updates

High number of new directors

Independent Director recently sold US$475k worth of stock

eFFECTOR Therapeutics, Inc. Announces Publication of Zotatifin Preclinical Data in Frontiers in Oncology

Independent Director recently sold US$407k worth of stock

Independent Director recently sold US$222k worth of stock

Independent Director recently sold US$917k worth of stock

Third quarter 2021 earnings released: EPS US$0.53

eFFECTOR: Developing New Class Of Cancer Therapies

CEO Compensation Analysis

CEO

Tenure

Compensation

Leadership Team

Average Tenure

Average Age

Board Members

Average Tenure

Average Age